Antimicrobial resistance in gonorrhoea: what is the way forward?

Yarwood, Trent

doi:10.1111/imj.15713

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gonorrhea' 2022). Globally, gonorrhea is a serious public health threat associated with significant socioeconomic consequences and a high incidence rate that reached a high of 82 million cases in 2021 (Unemo and Shafer 2015;Yarwood 2022;Vashishtha, Singh, and Kundu 2022). This number may be an underestimate because gonococcal infections can be asymptomatic and there is an absence of surveillance programs to track infections in several countries (Elhassanny, Abutaleb, and Seleem 2022).…”

Section: Introductionmentioning

confidence: 99%

Colonization efficiency of multidrug-resistant Neisseria gonorrhoeae in a female mouse model

Kikiowo,

Bandara,

Abutaleb

et al. 2023

Pathogens and Disease

View full text Add to dashboard Cite

The rapid occurrence of gonococcal resistance to all classes of antibiotics could lead to untreatable gonorrhea. Thus, development of novel anti-Neisseria gonorrhoeae drugs is urgently needed. N. gonorrhoeae FA1090 is the most used in gonococcal infection mouse models because of its natural resistance to streptomycin. Streptomycin inhibits the urogenital commensal flora that permits gonococcal colonization. However, this strain is drug-susceptible and cannot be used to investigate the efficacy of novel agents against multidrug-resistant N. gonorrhoeae. Hence, to test the in vivo efficacy of new therapeutics against N. gonorrhoeae resistant to the frontline antibiotics, azithromycin or ceftriaxone, we constructed streptomycin-resistant mutants of N. gonorrhoeae CDC-181 (azithromycin-resistant) and WHO-X (ceftriaxone-resistant). We identified the inoculum size needed to successfully colonize mice. Both mutants, CDC-181-rpsLA128G and WHO-X-rpsLA128G, colonized the genital tract of mice for 14 days with 100% colonization observed for at least 7 days. CDC-181-rpsLA128G demonstrated better colonization of the murine genital tract compared to WHO-X-rpsLA128G. Lower inoculum of WHO-X-rpsLA128G (105 and 106 CFU) colonized mice better than higher inoculum. Overall, our results indicate that CDC-181-rpsLA128G and WHO-X-rpsLA128G can colonize the lower genital tract of mice and are suitable to be used in mouse models to investigate the efficacy of anti-gonococcal agents.

show abstract

Section: Introductionmentioning

confidence: 99%